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ABSTRACT 
Idiopathic pulmonary fibrosis (IPF) is a 
progressive fibrotic lung disease with high 
mortality. Active Transforming Growth Factor 
1 (TGF1) is considered central to the 
pathogenesis of IPF. A major mechanism of 
TGF1 activation in the lung involves the 
epithelially restricted αvβ6 integrin. Expression 
of the αvβ6 integrin is dramatically increased in 
IPF. How v6 integrin expression is regulated 
in pulmonary epithlium is unknown. Here we 
identified a region in the β6 subunit gene 
(ITGB6) promoter acting to markedly repress 
basal gene transcription, which responds to both 
the Ets domain-containing protein Elk1 (Elk1) 
and the glucocorticoid receptor (GR). Both Elk1, 
and GR, can regulate v6 integrin expression 
in vitro. We demonstrate Elk1 binding to the 
ITGB6 promoter basally, and that manipulation 
of Elk1, or Elk1 binding, alters ITGB6 promoter 
activity, gene transcription and αvβ6 integrin 
expression. Crucially, we find that loss of Elk1 
causes enhanced Itgb6 expression and 
exaggerated lung fibrosis in an in vivo model of 
fibrosis, whereas the GR agonist Dexamethasone 
inhibits Itgb6 expression. Moreover Elk1 
dysregulation is present in epithelium from 
patients with IPF. These data reveal a novel role 
for Elk1 regulating ITGB6 expression and 
highlight how dysregulation of Elk1 can 
contribute to human disease. 
INTRODUCTION 
The prognosis of idiopathic pulmonary fibrosis 
(IPF) patients is poor, with 5-year survival rates 
worse than most cancers [1] and the incidence is 
rapidly increasing [2]. IPF is characterised by 
excessive matrix deposition within the lung 
interstitium leading to deteriorating pulmonary 
function and ultimately death. IPF pathogenesis 
is poorly understood, however, the current 
paradigm suggests that recurrent epithelial injury 
and failing repair promotes expansion and 
transdifferentiation of myofibroblasts within the 
interstitium [3]. Improved understanding of the 
mechanisms driving fibrogenesis is critical for 
the development of urgently needed new 
therapeutics. 
Transforming growth factor β1 (TGFβ1) is a key 
cytokine implicated in the development of 
fibrosis [4]. It has profound effects on both 
epithelial cells and fibroblasts, two of the key 
effector cells in fibrogenesis, and mediates many 
of the characteristic pathologic features of 
fibrosis including epithelial cell apoptosis, 
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myofibroblast transdifferentiation and 
subsequent collagen production [5, 6]. For 
TGFβ1 to exert any biological effect it must first 
be activated, and activation by the αvβ6 integrin 
is an important feature in experimental models 
of fibrosis in multiple organ systems [7-12].  
Fundamentally, high levels of αvβ6 integrins 
have been demonstrated in lung tissue from 
patients with pulmonary fibrosis [9, 13] and are 
associated with a worse prognosis [14]. 
Similarly, levels of β6 subunit mRNA (ITGB6) 
correlate with increasing severity of fibrosis in 
the liver [15]. The molecular mechanisms 
regulating expression levels of αvβ6 integrins 
are, therefore, likely to be critical for ensuring 
normal repair in response to injury rather than 
pathological fibrosis. Such mechanisms, 
however, have not been investigated in detail.  
It has previously been shown that TGF1 
increases ITGB6 levels and elevates expression 
of αvβ6 integrins by guinea pig airway epithelial 
cells in vitro [16] and a positive feedback loop 
of αvβ6-mediated TGFβ1 activation promoting 
enhanced integrin expression in the lung has 
been proposed [17]. It is possible that TGFβ1-
independent pathways may also contribute to 
ITGB6 regulation. For example a potential role 
for ets-1 during increased transcription of the 
ITGB6 gene has been suggested [18] and over-
expression of active Stat3 leads to increased 
ITGB6 expression in carcinogenesis [19]. 
However, whether these mechanisms are 
involved in upregulation of ITGB6 in pulmonary 
fibrosis is unknown. 
This study aimed to investigate the molecular 
mechanisms driving ITGB6 expression in lung 
epithelial cells, and investigate the importance of 
these pathways in fibrogenesis. We have 
identified a novel region of the ITGB6 promoter 
responsible for repressing transcription and 
demonstrate that Elk1, as well as the 
glucocorticoid receptor (GR), can act to repress 
the ITGB6 gene. We demonstrate that Elk1 
deficiency in vivo enhances Itgb6 expression and 
exacerbates bleomycin-induced fibrosis in mice, 
whereas the GR agonist Dexamethasone 
represses Itgb6 expression. Finally, we show that 
lung tissue from pulmonary fibrosis patients 
displays reduced Elk1 expression, associated 
with reduced Elk1 binding to the ITGB6 
promoter. These data highlight a novel and 
crucial function of the transcription factor Elk1 
in modulating v6 expression in the lung.  
EXPERIMENTAL PROCEDURES 
Cell Lines and Reagents 
Immortalised human bronchial epithelial cells 
(iHBECs; a kind gift from Professor Jerry Shay, 
University of Texas) or small airway epithelial 
cells (SAECs; Lonza, UK) were used for many 
in vitro experiments. The iHBEC immortalised 
cell line was selected over primary alveolar 
epithelial cells for the majority of in vitro studies 
due to the technical advantages in performing 
molecular mechanistic studies such as 
transfections and ChIP in these cells. iHBECs 
retain their ability to differentiate into basal, 
mucin-producing and ciliated epithelial cells 
[20]. Furthermore, iHBECs are one of the only 
immortalised or transformed lung epithelial cell 
lines that retains their αvβ6 integrin expression 
in vitro. iHBECs were cultured in keratinocyte 
serum free medium (K-SFM; Lonza, UK) 
containing bovine pituitary extract (Lonza, UK), 
epidermal growth factor (Lonza, UK), G418 
(Sigma-Aldrich, UK), puromycin (Sigma-
Aldrich, UK), penicillin and streptomycin (both 
from Sigma-Aldrich, UK).  
Primary small airway epithelial cells (SAECs) 
were used to confirm some findings obtained in 
iHBECs. They were cultured in small airway 
growth media (Lonza, UK) containing the 
supplied supplements. All cells were growth 
arrested in supplement-free media for 24 hours 
prior to the start of experiments, except in the 
case of transfection experiments. To assess 
binding of endogenous Elk1 to exogenous 
ITGB6 promoter constructs we used the 
adenosquamous carcinoma cell line H647 after 
determining that these cells exhibit high 
expression level of endogenous Elk1. H647 cells 
were cultured in Roswell Park Memorial 
Institute (RPMI; Sigma Aldrich, UK) media 
with 10% foetal calf serum (FCS), L-glutamine, 
penicillin and streptomycin. 
Elk1 and GAPDH antibodies for western 
blotting were supplied by Cell Signalling 
Technology, UK. All siRNA constructs and the 
associated reagents were provided by Santa Cruz 
Biotechnology, USA. Formaldehyde, glycine, 
dexamethasone and progesterone were supplied 
by Sigma Aldrich, UK. PE-labelled or FITC-
labelled secondary antibodies for flow 
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cytometry, TriZol reagent, zysorbin, TA cloning 
kit and T4 ligase were supplied by Invitrogen, 
UK. All reagents required for the synthesis of 
cDNA from RNA, including Moloney murine 
virus reverse transcriptase, and all plasmids not 
provided by Addgene or a collaborator plus 
Transfast reagent were provided by Promega, 
UK. Kapa Taq polymerase for use in QPCR 
reactions was supplied by Kapa Biosystems, 
USA. All ChIP antibodies were obtained from 
Abcam, UK. 
Flow Cytometry 
Flow cytometry was used to assess αvβ6 cell 
surface expression as previously described [13]. 
Briefly, iHBECs were labelled with 10μg anti-
αvβ6 antibody (clone 6.3G9) [21] and a PE-
labelled anti-mouse secondary antibody. A 
secondary antibody only negative control was 
performed. Fluorescence was assessed using a 
BD FACSDIVA flow cytometer.  
Quantitative Polymerase Chain Reaction (Q-
PCR) 
Gene expression of both human and murine 
genes was measured using an MxPro3000 
instrument (Stratagene, CA, USA) and Kapa Taq 
using the following primer sequences: human 
ITGB6 sense 5’-
AAACGGGAACCAATCCTCTGT-3’ and anti-
sense 5’- GCTTCTCCCTGTGCTTGTAGGT-
3’, human β2-microglobulin (B2M) 5’-
AATCCAAATGCGGCATCT-3’ and anti-sense 
5’-GAGTATGCCTGCCGTGTG-3’, human 
ELK1 sense 5’-
CCACCTTCACCATCCAGTCT-3’ and anti-
sense 5’-TCTTCCGATTTCAGGTTTGG-3’, 
murine Itgb6 sense 5’-
TCTGAGGATGGAGTGCTGTG-3’ and anti-
sense 5’-GGCACCAATGGCTTTACACT-3’.  . 
All QPCR reactions were performed at an 
annealing temperature of 60°C. Amplification of 
a single DNA product was confirmed by melting 
curve analysis. Data were expressed as relative 
expression using the ΔΔCt equation. 
Generation of ITGB6 Promoter Deletion 
Mutant Series 
The 1.1kb insert was excised from pGL2-ITGB6 
[18] and ligated into pGL3 vector (Promega, 
UK) using T4 ligase then sequenced to verify 
presence of insert. Progressively truncated forms 
of the reporter (see Figure 1A) were amplified 
by PCR and TA cloned with a commercially 
available kit (Invitrogen, UK). The purified 
inserts were then ligated into the pGL3 vector 
using T4 ligase (Invitrogen, UK) and sequenced 
to confirm the presence of the correct insert. 
Reporter Construct Transfections 
Transient transfections were performed using 
Transfast (Promega, UK) transfection reagent 
using 0.75μg reporter plasmid DNA with 7.5ng 
renilla luciferase DNA at a 1:2 DNA: Transfast 
ratio. Briefly, cells were seeded at 2x10
5
 cells/ml 
then cultured for 8 hours in supplemented 
KSFM media prior to transfection overnight in 
unsupplemented KSFM media. The following 
day cells were stimulated as required for the 
experiment. To assess of binding of endogenous 
Elk1 to ITGB6 reporter constructs 0.75μg 
reporter plasmid DNA was transfected in to 
H647 cells at a 1:2 DNA: Transfast ratio for 24 
hours.  
siRNA Transfections 
siRNA directed towards Elk1, GR or a control 
siRNA were transfected into iHBECs using the 
siRNA transfection reagents and protocol 
provided by Santa Cruz Biotechnology. 40pmol 
of siRNA was used per well of cells in a 24 well 
plate. Cells were transfected for 24 hours prior 
to the start of an experiment to allow sufficient 
knockdown of target protein. 
Site Directed Mutagenesis (SDM) 
Site directed mutagenesis was performed using 
the QuickChange II Site Directed Mutagenesis 
kit (Agilent, UK) according to the 
manufacturer’s instructions. The Elk1 binding 
sites located at -772 (reverse strand) and -752 
were mutated from GGAA to AAGA using the 
following primers: sense 5’-
CCCCCAGGGTGTTCTTCAAAGAGGTGTTT
TGAGATTTGTAGAGTC-3’ and anti-sense 5’-
GACTCTACAAATCTCAAAACACCTCTTTG
AAGAACACCCTGGGGG-3’. All constructs 
were sequenced prior to use in experiments to 
confirm the presence of the correct mutation. 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) allowed 
the binding of proteins to the ITGB6 promoter to 
be determined. The ChIP-IT Express kit (Active 
Motif, UK) was used to assess binding in 
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cultured cells as previously described for airway 
smooth muscle cells [22]. Briefly, cells were 
fixed with 1% formaldehyde for 5 minutes and 
lysed prior to shearing of the cellular chromatin 
by sonication using an Epishear sonicator 
(Active Motif, UK). 25μg total chromatin was 
immunoprecipitated with 10μg antibody and 
Protein G magnetic beads. ChIP QPCR data 
were normalised to input chromatin (i.e. the 
amount of total chromatin present in the IP 
sample) then expressed as relative binding 
compared with control sample using the ΔΔCt 
equation. ChIP QPCR primer sequences were as 
follows using an annealing temperature of 60°C: 
ITGB6 promoter -934 to -753 sense 5’-
CATGCTTACCCAGGAATGCT-3’ and anti-
sense 5’-ACACCCTGGGGGAAAAATAC-3’, 
ITGB6 promoter -1604 to -1497 sense 5’-
ACTGCCCTCCAGCCTAGAA-3’ and anti-
sense 5’-TTGACAGAAACTAAATGCCCAA-
3’. 
ChIP on human lung tissue was performed by 
first creating a single cell suspension by passing 
the tissue through a 100m cell strainer. The 
cellular chromatin was then cross-linked in 1% 
formaldehyde for 5 minutes. The crosslinking 
was reversed with glycine, the cells lysed in 
10% SDS, and then the chromatin was sheared 
by sonication using an Epishear sonicator 
(Active Motif, UK). 100µg of total tissue 
chromatin was subjected to immunoprecipitation 
with 10µg of Elk1 antibody overnight. 
Antibody-bound DNA was extracted using 
Zysorbin. 
ChIP was employed to assess binding of 
endogenous Elk1 protein to exogenous ITGB6 
promoter plasmid constructs. H647 cells were 
used, which we found to express high levels of 
endogenous Elk1 (data not shown). Following 
transfection and expression of exogenous 
constructs the cells were formaldehyde fixed and 
processed as stated above for other cultured 
cells. QPCR of the resulting immunoprecipitated 
(IP) DNA was performed using primers directed 
against the luciferase sequence of the pGL3 
plasmid in order to assess Elk1 binding only to 
exogenous DNA, not endogenous DNA (sense 
5’-GCTTTTACAGATGCACATATC-3’ and 
anti-sense 5’-
CCATACTGTTGAGCAATTCACG-3’). 
Relative binding was normalised to input 
chromatin luciferase critical threshold (ct) signal 
(i.e. amount of luciferase plasmid DNA present) 
to ensure differences in transfection efficiency 
between the constructs did not affect detection 
of Elk1 binding levels. Data were expressed as 
relative binding to the non-mutated ITGB6 
promoter construct using the ΔΔCt equation. 
Western Blots 
Human lung tissue was homogenised using a 
mechanical tissue tearer in ice-cold lysis buffer 
(20mM Tris-HCl, 137mM NaCl, 1% Triton X-
100, 2mM EDTA, 10% glycerol – all supplied 
by Sigma-Aldrich, UK) supplemented with 
protease and phosphatase inhibitors (Complete 
Mini protease inhibitor tablet and Phos-stop 
inhibitor tablets; Roche, UK). Expression of 
Elk1, GR and GAPDH proteins was measured 
by western blotting as previously described for 
Smad2/3 [23]. Briefly, protein concentrations in 
each sample were determined using a 
bicinchroninic assay (BCA; Pierce, UK) 
according to the manufacturer’s instructions and 
using increasing concentrations of bovine serum 
albumin as a standard curve. 100µg of total 
protein was loaded in to each lane of an SDS-
PAGE gel and a current of 150V was applied for 
60 minutes. The gel was transferred on to a 
polyvinylidene membrane, blocked with 5% 
non-fat milk, then probed with the following 
antibodies overnight: rabbit anti-Elk1 (Cell 
Signalling Tehcnology, UK, #9182) at 1:1000 
dilution, rabbit anti-GR (Cell Signalling 
Technology, UK, #3660) at 1:1000 dilution, goat 
anti-GAPDH (V-18; Santa Cruz Biotechnology, 
USA) at 100ng/ml. All horseradish peroxidase 
conjugated secondary antibodies were used at a 
333µg/ml and were purchased from Dako, UK. 
Western blot films were scanned and band 
density calculated by inverting the image and 
measuring mean grey pixels using Adobe 
Photoshop CS5 Extended (32 bit, Version 12.1).  
In vivo Bleomycin Model of Pulmonary 
Fibrosis 
Male Elk1
-/0
 [24] and wild-type mice (aged 5-7 
weeks) were treated with either 0 or 60 IU 
bleomycin sulphate in 50 l saline via the 
oropharyngeal route under isofluorane 
anaesthesia (2.5%, 2 L/min flow of oxygen). All 
tissue was collected 28 days post bleomycin 
treatment. The lungs were either excised and 
snap-frozen at -80°C for mRNA and 
hydroxyproline assessment, or insufflated with 
formalin at constant gravitational pressure (20 
5 
cm H2O) then paraffin wax embedded for 
histology and immunohistochemistry. 
To assess the role of GR in regulating Itgb6 
mRNA in vivo male 6 week old C57/black6/J 
mice were treated with either 60IU bleomycin in 
50µl saline, or saline only as a control, via the 
oropharyngeal route under isoflourane 
anaesthesia (2.5%, 2 L/min). All animals also 
received daily treatment with either 1mg/kg 
dexamethasone (100µl volume) or PBS only as a 
control via intraperitoneal injection. After 14 
days the lungs were removed and snap-frozen at 
-80°C for subsequent RNA analysis.  
Immunohistochemistry 
5 μm thick sections of paraffin wax embedded 
lung tissue of murine and human origin was 
subjected to immunohistochemistry to evaluate 
expression levels of the αvβ6 integrin as 
previously described [13]. An antibody directed 
against murine αvβ6 (clone ch2.A1) and an 
antibody directed against human αvβ6 (clone 
6.3G9) were kindly provided by Biogen Idec, 
USA. Murine tissue from the bleomycin model 
of pulmonary fibrosis was also subjected to 
immunohistochemistry to detect levels of 
pSmad2. Tissue sections were boiled in 10 mM 
citrate buffer to retrieve endogenous antigens 
then exposed to anti-pSmad2 antibody (1:500 
dilution, Cell Signalling, UK) overnight. 
Staining was visualised with DAB as for αvβ6. 
Human lung tissue from four fibrotic and four 
non-fibrotic donors was subjected to 
immunohistochemistry to detect levels of either 
αvβ6 (see above for αvβ6) or Elk1. For Elk1 
tissue was dewaxed and rehydrated and then 
boiled in 10 mM citrate buffer. Following 
blocking in 5% donkey serum the sections were 
incubated overnight with either Elk1 antibody 
(1.1µg/ml, Abcam clone E277). Staining was 
visualised using DAB. All staining was 
visualised using a Nikon 90i light microscope 
and NIS-Elements image acquisition software.  
Quantification of pSmad2 Positive Nuclei 
Quantification was performed using a Nikon 
Eclipse 90i microscope and Nikon NIS Elements 
software. Five random fields of view at x20 
magnification were observed per tissue section. 
All brown nuclei present in the the field of view 
were counted.  
Masson’s Trichrome Histological Staining 
5 μm thick histological sections of lung tissue 
were dewaxed and rehydrated using xylene and 
decreasing concentrations of ethanol. The tissues 
were incubated overnight at room temperature in 
Bouin’s solution. The lung tissue was then 
subjected to consecutive histological staining in 
Weigert’s solution (5 minutes), Biebrich scarlett 
acid fuchsin (5 minutes), phosphomolybolic 
acid/ phototungstic acid (seven minutes), analine 
blue (5 minutes) and 1% acetic acid (1 minute). 
The sections were then dehydrated and imaged 
using Nikon Eclipse 90i microscope.  
Isolation of mRNA from Lung Tissue 
Human and murine lung tissue was ground to 
powder in liquid nitrogen using a pestle and 
mortar. Frozen lung tissue was then added to 
TriZol reagent (1 ml TriZol per 0.5 g tissue) and 
incubated on ice for 5 minutes prior to the 
addition of chloroform (200 μl/ml Trizol). The 
samples were centrifuged at 11,000 g for 20 
minutes to allow phase separation then the 
aqueous layer transferred to a new tube. RNA 
was precipitated by addition of 500 μl isopropyl 
alcohol and 1 μl glycogen and centrifuged. The 
RNA was washed in 75% ethanol prior to being 
re-suspended in nuclease free water. 
Hydroxyproline Assay 
Hydroxyproline levels in murine lung tissue 
were measured as previously described [25]. 
Briefly, lung tissue was hydrolysed in 6 N HCl 
at 100°C overnight and the hydrosylate 
resuspended in water. 1.4% chloramine T in 
10% isopropanol and 0.5 M sodium acetate were 
added for 20 minutes, followed by Erlich’s 
solution for 15 minutes at 65°C. Absorbance 
was measured at 550 nm. 
Human Tissue and Ethical Approval 
Lung tissue from pulmonary fibrosis patients 
(PF) was obtained either post mortem or from 
lung transplant patients following informed, 
written consent and ethical review (Ethical 
approval numbers: Nottingham Respiratory 
Research Unit 08/H0407/1; Papworth Hospital 
Research Tissue Bank, REC: 08/H0304/56; 
UCSF IRB #10-00198, South East Scotland 
SAHSC Bioresource 06/S1101/41). In all cases 
the pathological diagnosis was usual interstitial 
pneumonia and the clinical diagnosis IPF was 
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made based on ATS/ERS consensus criteria 
[26]. Non-fibrotic human lung tissue was 
obtained from non-cancerous tissue removed 
during surgery or from donor lungs unsuitable 
for transplant. All experiments were performed 
in accordance with the WMA Declaration of 
Helsinki.  
Animal studies using bleomycin were approved 
by the University of Nottingham Ethical Review 
Committee and were performed under Home 
Office Project and Personal License authority 
within the Animals (Scientific) Procedures Act 
1986. Animals received free access to food and 
water at all times.  
Statistics 
All cell-based experiments were repeated three 
times and expressed as mean data from the three 
independent experiments. Statistical significance 
was determined by either T test when comparing 
two data sets or ANOVA for comparing multiple 
data sets. Data from experiments comparing 
pulmonary fibrosis (PF) and control non-fibrotic 
(NF) human tissues were not normally 
distributed therefore the non-parametric Mann 
Whitney U test was used to determine 
significance. P<0.05 was accepted as significant 
in all cases. 
RESULTS 
The ITGB6 gene promoter contains a putative 
repressor region 
To investigate the presence of transcriptional 
regulatory regions within the ITGB6 gene 
promoter we created a series of truncated ITGB6 
promoter luciferase reporter constructs from the 
1.1kb ITGB6 promoter reporter used by others 
[18] (See Figure 1A). With progressively 
decreasing size, transcription factor binding sites 
are lost from the reporter constructs. This series 
of reporter constructs was transfected in to 
iHBECs and luciferase activity measured after 
four hours. Loss of the most distal regions of the 
ITGB6 promoter led to dramatic increases in 
basal promoter activity (Figure 1B). The 
increase in basal promoter activity was greatest 
when the -818 to -731 region of the promoter 
was absent suggesting this region contains 
important negative regulatory elements. In silico 
analysis using Transcription Element Search 
Software (University of Pennsylvania, USA) 
indicated binding sites for several transcription 
factors within the region -818 to -731. A 
schematic diagram showing this putative 
repressor region is shown in Figure 1C.  
Elk1 Represses ITGB6 and v6 expression 
in vitro 
Previous studies have suggested a role of ets 
family transcription factors in regulating the 
ITGB6 promoter [18]. Therefore, we initially 
investigated the role of Elk1 in ITGB6 
regulation. Using chromatin 
immunoprecipitation (ChIP) we demonstrated 
that Elk1 bound to the putative repressor region 
of the ITGB6 promoter in lung epithelial cells 
under basal conditions, but binding was not 
detected at a control region of the promoter 
upstream of the repressor region (Figure 2A). 
Site directed mutagenesis (SDM) of Elk1 
binding motifs was utilised to investigate the 
effect of interrupting binding of Elk1 to the 
ITGB6 promoter, which contains two Elk1 
binding sites within the putative repressor region 
(at -772 and -752). ChIP was used to assess 
binding of endogenous Elk1 protein to the 
exogenous mutated and non-mutated promoter 
constructs. Binding of endogenous Elk1 to the 
exogenous, unmutated pGL3-ITGB6 construct 
was detected, however, binding above an IgG 
control was not detected when either Elk1 site 
was mutated individually, or when both sites 
were mutated simultaneously (Figure 2B).  
Following confirmation that Elk1 was unable to 
bind to the ITGB6 promoter when the binding 
sites were mutated, the effect of mutating the 
Elk1 binding sites on promoter activity was 
assessed. Mutation of the Elk1 binding site at -
772 resulted in a small but significant rise in 
ITGB6 promoter activity, whereas mutation of 
the binding site at -752 had no significant effect 
(Figure 2C). However, mutation of both binding 
sites together resulted in a larger increase in 
ITGB6 promoter activity, which was greater than 
the increase observed when the -772 site was 
mutated alone (Figure 2C).  
To determine whether Elk1 repressed ITGB6 
mRNA expression we utilised an Elk1 siRNA 
that reduced Elk1 protein and mRNA expression 
compared with control siRNA (Figures 2D and 
2E).  Transfection of Elk1 siRNA increased 
basal ITGB6 promoter activity (Figure 2F), 
suggesting a loss of basal transcriptional 
repression. Supporting these molecular studies 
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we demonstrated that Elk1 siRNA also led to a 
significant increase in v6 cell surface protein 
levels two days following transfection (Figure 
2G and H). These data demonstrate that Elk1 
regulates in vitro lung epithelial cell αvβ6 
integrin expression. 
Glucocorticoid Receptor but not Progesterone 
Receptor, represses v6 expression 
The repressor region identified contains a 
number of putative transcription factor binding 
sites (Figure 1C), and the degree of repression 
mediated by Elk1 was considerably lower than 
observed by deletion of the complete repressor 
region. We therefore hypothesised that other 
transcription factors may be contributing to 
ITGB6 repression. The receptors for 
glucocorticoids and progesterone had been 
identified in the repressor region therefore we 
investigated the effect of these hormones on 
ITGB6 expression. Dexamethasone had no effect 
on basal activity of the full length ITGB6 
promoter after four hours but inhibited TGF-
induced increases in ITGB6 promoter activity in 
iHBECs (Figure 3A). However, treatment of 
SAECs with dexamethasone for three days 
resulted in a reduction in cell surface expression 
of αvβ6 integrins (Figure 3B and 3C). 
Additionally a siRNA targeting GR, which 
reduced GR protein expression (Figure 3D), 
caused a small, but consistent increase in αvβ6 
expression over two days (Figure 3E and 3F). 
Similar to dexamethasone, progesterone had no 
significant effect on basal ITGB6 promoter 
activity but abrogated TGF-induced increases 
in promoter activity (Figure 3G). However, 
progesterone had no significant effect on ITGB6 
mRNA expression over 24 hours (Figure 3H) 
nor had any effect on αvβ6 cell surface 
expression in SAECs over three days (Figure 
3I).  These data suggested that whilst 
glucocorticoids may affect ITGB6 expression, 
progesterone was unlikely to be involved in 
v6 regulation.   
Having identified two transcription factors (Elk1 
and GR) capable of binding the putative 
repressor region, and repressing ITGB6 and 
αvβ6 we sought to determine whether they co-
regulated αvβ6 expression. Firstly, we utilised a 
combination of dexamethasone treatment, to 
activate GR, and Elk1 siRNA and assessed the 
effect on αvβ6 expression. Confirming the data 
shown in Figure 2G transfection of iHBECs with 
Elk1 siRNA caused a modest, but significant 
increase in αvβ6 expression (Figure 4A). 
However, activation of the GR with 
dexamethasone for two days did not effect αvβ6 
levels in the presence of either control or Elk1 
siRNA (Figure 4A). We next investigated the 
effect of dexamethasone treatment on TGFβ-
induced increases in αvβ6 expression. Despite 
showing a trend towards reducing TGFβ-
induced αvβ6 expression, dexamethasone did 
not have a statistically signficiant effect on 
TGFβ-induced increases in αvβ6 expression in 
iHBECs after two days (Figure 4B). Finally,  
iHBECs were transfected with Elk1 or GR 
siRNAs, or both siRNAs in combination and 
αvβ6 expression was measured in unstimulated 
and TGFβ stimulated cells. Both Elk1 and GR 
siRNA increased basal αvβ6 expression as 
previously shown, although transfection of both 
siRNAs did not act synergystically to further 
enhance αvβ6 cell surface levels (Figure 4C). 
Transfection with Elk1 and GR siRNA had a 
similar effect on TGFβ stimulated cells although 
the increase was not statistically significant 
compared with TGF alone (Figure 4C).  
Loss of Elk1 in vivo results in an exaggerated 
response to bleomycin-induced lung fibrosis. 
Although the in vitro data suggested that Elk1 
was unlikely to mediate complete repression of 
the ITGB6 promoter, we hypothesised that even 
moderate effects on epithelial v6 integrin 
expression were likely to be important in 
response to injury. Therefore, to determine 
whether global loss of Elk1 was sufficient to 
increase Itgb6 expression in vivo and exacerbate 
fibrotic responses we employed the bleomycin 
model of lung fibrosis. Elk1
-/0
 male mice, and 
wild-type littermate controls (Elk1
+/0
), were 
instilled with saline or 60 IU of bleomycin. 
Lungs were harvested 28 days following 
bleomycin instillation then lung fibrosis and 
Itgb6 mRNA levels measured. Bleomycin 
increased levels of Itgb6 mRNA in homogenates 
of Elk1
-/0
 and Elk1
+/0
 whole lung tissues, 
however, there were significantly greater levels 
of Itgb6 mRNA in the lungs of Elk1
-/0
 animals 
treated with bleomycin (Figure 5A).  
Lung fibrosis was quantified by measuring 
levels of hydroxyproline in lung tissue and by 
assessing histology using Masson’s trichrome 
stain. Bleomycin treatment increased lung 
hydroxyproline levels in both Elk1
+/0
 and Elk1
-/0
 
animals, however, lungs from bleomycin treated 
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Elk1
-/0
 mice contained significantly higher levels 
of hydroxyproline compared with bleomycin-
treated Elk1
+/0
 animals (Figure 5B).  To confirm 
that deposition of collagen in the lungs, in 
response to bleomycin, was greater in Elk1
-/0
 
animals compared with control animals 
histological sections of lung tissue were stained 
with Masson’s trichrome. Low power, stiched 
images of entire lung lobes demonstrate the 
patchy nature of lung fibrosis following 
bleomycin-induced lung injury but show that the 
areas of fibrosis were considerably larger in the 
Elk1
-/0
 animals compared with the control 
animals (Figures 5C and D), and this was 
confirmed in high power images (Figure 5E i-
iv). Lung tissue from these animals was also 
stained by immunohistochemistry for αvβ6 
integrins. There was no evidence of v6 
protein expression in lungs of injured mice (data 
not shown) consistent with previous reports [25]. 
Although expression of the αvβ6 integrin was 
evident in areas of lung damage in both Elk1
-/0
 
and Elk1
+/0
 animals, expression was markedly 
increased in the Elk1
-/0
, compared with wild-type 
control, animals (Figure 5E, panels v and vii). 
Furthermore, Elk1
-/0
 animals demonstrated a 
trend towards increased pSmad2 staining 
compared with Elk1
+/0
 animals (Figure 5E, 
panels vi and viii and Figure 5F), consistent with 
reduced Elk1 expression leading to enhanced 
expression of TGF-activating integrins. Taken 
together these data support the hypothesis that 
Elk1 is capable of suppressing Itgb6 mRNA and 
αvβ6 expression in vivo, and ultimately limit the 
fibrotic response to injury in vivo.  
Having identified that GR could also repress 
ITGB6 in vitro we evaluated its effect in vivo. 
Animals were treated with bleomycin to induce 
lung injury and Itgb6 expression, or saline, and 
received daily i.p. injections of either 
dexamethasone, or PBS control. Itgb6 mRNA 
levels were determined in the lungs after 14 
days. There was a clear trend towards reduced 
Itgb6 expression in both the saline and 
bleomycin groups treated with daily 
dexamethasone compared with the groups 
treated with daily PBS (Figure 5G), however this 
did not reach statistical significance. However, 
when the data were analysed to determine any 
effect of dexamethasone irrespective of the 
presence of lung injury, there was a signficiant 
reduction in Itgb6 mRNA following 
dexamethasone treatment compared with PBS 
treatment (p=0.01). This effect was also 
observed after 21 days of treatment (Data not 
shown). These data confirm the in vitro 
observations and show that Elk1 and GR can 
regulate expression of Itgb6 in murine lung. 
The repressor of ITGB6 transcription, Elk1, 
is reduced in pulmonary fibrosis 
Having identified that Elk1 is important for 
repression of ITGB6 expression in the lung we 
hypothesised that this pathway would be 
dysregulated in human disease. We have 
previously demonstrated that ITGB6 mRNA 
levels are increased in lung tissue homogenates 
from lung fibrosis patients [25], which we again 
found in this study (Figure 6A). ChIP analysis 
demonstrated that there was binding of Elk1 to 
the ITGB6 promoter in non-fibrotic human lung 
tissue, and that there was reduced binding in 
samples from patients with PF (p=0.05; Figure 
6B). It was clear that in some patients with 
pulmonary fibrosis (PF) there was no detectable 
binding of Elk1 to the ITGB6 promoter above 
IgG controls (Figure 6B), therefore levels of 
Elk1 protein were assessed by western blot in 
fibrotic (PF) and non-fibrotic (NF) lung tissue 
samples. Elk1 was expressed in all control 
samples tested (Figure 6C and 6D) but levels 
were lower, and in some cases undetectable, in 
the PF tissue tested. Quantification of the 
western blot signals by densitometry 
demonstrated that PF patients had significantly 
less Elk1 protein than controls (Figure 6C). 
Specificity of the antibody used was confirmed 
by probing protein samples from both wild-type 
and Elk1
-/0
 animals. Elk1 protein was detected in 
wild-type animals but not Elk
-/0
 animals (Figure 
6E). 
To assess expression of Elk1 protein 
macroscopically in human lung tissue serial 
sections of paraffin wax embedded lung tissue 
from NF (n=4) and PF (n=4) donors were 
immunostained for both v6 and Elk1. 
Confirming previous reports [13] NF donors had 
low levels of v6 expression within the 
alveolar epithelium (Figure 6F, panel i). In 
contrast lung tissue from PF donors 
demonstrated marked expression of v6 
integrins within the alveolar epithelium that was 
particularly evident around regions of fibrosis 
(Figure 6F, panel ii). Supporting a role for Elk1 
being responsible for negative regulation of 
v6 integrins and confirming that Elk1 protein 
expression is aberrant in fibrosis we found that 
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NF donors had high levels of epithelial Elk1 
protein expression whereas PF donors had 
minimal expression of Elk1 within the lung 
epithelium (Figure 6F, panels iii and iv). 
DISCUSSION 
IPF is a progressive lung disease with extremely 
poor survival and no effective treatments.  
Activation of TGFβ via αvβ6 integrins, the 
expression of which is limited to epithelial cells, 
is a fundamental process in the pathogenesis of 
pulmonary fibrosis [7, 9, 11]. Interactions 
between lung epithelial cells and fibroblasts, 
partly through epithelial cell αvβ6-mediated 
TGFβ activation, are now thought to be critical 
to the development and progression of lung 
fibrosis [4]. A common observation in IPF 
patients, and in other fibrotic disorders, is the 
upregulation of αvβ6 integrins within the 
epithelium [9, 12, 14, 15]. The molecular 
mechanisms driving enhanced αvβ6 expression, 
however, have not been fully investigated. In the 
current study we have highlighted a region of the 
ITGB6 gene promoter responsible for repressing 
basal gene transcription and, fundamentally, 
have identified a novel and important function 
for the transcription factor Elk1 in fibrosis as a 
negative regulator of ITGB6 and αvβ6 integrins 
in epithelial cells. 
Previous studies have suggested that 
recombinant Elk1 reduces activity of an 
exogenous ITGB6 promoter in the HEK293 cell 
line [18]. Our data are consistent with these 
findings and demonstrates that loss of Elk1, or 
interruption of the ability of Elk1 to bind to the 
ITGB6 promoter, increases ITGB6 promoter 
activity in lung epithelial cells, which can, in 
turn, lead to increased expression of v6 
integrins in vitro. Furthermore, loss of Elk1 in 
vivo increased levels of Itgb6 mRNA and 
collagen deposition in a bleomycin model of 
lung fibrosis. Elk1 is a ternary complex factor 
that is commonly thought of as an activator of 
transcription when phosphorylated. However, it 
also contains an R domain that can potently 
repress transcription [27]. The role of Elk1 
phosphorylation has not yet been determined on 
ITGB6 expression, and may prove to be an 
important regulatory pathway. It is possible that 
dynamic regulation between unphosphorylated 
Elk, which functions as a transcriptional 
repressor, and phosphorylated Elk1, which can 
act as an transcriptional activator may be 
important in repair processes and is the focus of 
current studies.  
Other putative repressors of the ITGB6 promoter 
highlighted by in silico analysis included the 
progesterone and glucocorticoid receptors (PR 
and GR). Both PR and GR are expressed in the 
normal lung [28, 29], and although the effects of 
progesterone on ITGB6 expression have not 
previously been investigated either in the lung or 
in other tissues, it has been shown to modulate 
the expression of several other integrin subunits 
including the 2 and 11 subunits, as well as 
11 and v3 integrins in the placenta and 
endometrium [30, 31]. However, we found no 
convincing effect of progesterone on basal 
ITGB6 promoter activity, ITGB6 mRNA levels 
or cell surface v6 integrin levels suggesting 
that PR is not a major contributor to repression 
of ITGB6 in lung epithelial cells.  
In contrast with progesterone, dexamethasone 
was able to inhibit TGF1-induced ITGB6 
promoter activity, inhibit basal v6 integrin 
cell surface expression, and showed a trend 
towards reducing TGFβ-induced αvβ6 
expression in vitro. Furthermore, confirming our 
in vitro data, activation of GR in vivo using daily 
treatment with dexamethasone led to reduced 
expression of Itgb6 mRNA in the lung. Although 
it is possible that the inhibition of v6 integrin 
expression is a direct result of GR activation 
with consequent binding to, and repression of, 
the ITGB6 promoter we do not favour this 
hypothesis. Our data suggest that dexamethasone 
does not affect basal promoter activity, but 
rather inhibits TGF-1-induced ITGB6 
expression. Furthermore, it has previously been 
shown that GR can interrupt TGF/Smad3 
mediated plasminogen activator inhibitor-1 
(PAI1) expression via a physical interaction with 
the transcriptional activation functions of Smad3 
[32]. Since TGF- has been postulated as a 
positive regulator of v6 integrins via an 
autocrine loop [17] we would hyothesise that 
GR reduces αvβ6 protein expression via 
interrupting this TGF--mediated autocrine 
loop.  
The effect of siRNA-induced knock-down of 
Elk1 on both ITGB6 promoter activity and αvβ6 
integrin expression was relatively modest and 
the effect of Elk1 siRNA does not completely 
recapitulate the effect of loss of the entire 
repressor region from the ITGB6 promoter. 
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Efficiency of the siRNA transfection is unlikely 
to have reached 100%, which is supported by the 
observation that transfection with Elk1 siRNA 
did not result in 100% knock-down of Elk1 
protein or mRNA. Furthermore, the process of 
transfecting cells in vitro can often result in cell 
injury [33, 34] and it is well documented that 
epithelial cell injury results in upregulation of 
αvβ6 [8, 12], which raises the possibility that 
transfection of the control siRNA might have 
increased αvβ6 expression therefore reducing the 
effect “window” observed when comparing Elk1 
siRNA with control siRNA. Unfortunately, the 
nuclear location of Elk1 made alternative 
methods of inhibiting Elk1 difficult.  
Importantly, the repressor region of the ITGB6 
promoter contains multiple transcription factor 
binding sites, many of which may also exhibit 
repressor functions on the ITGB6 gene. In 
addition to Elk1 our data highlight a potential 
role for GR in suppressing αvβ6 expression in 
vitro and Itgb6 in vivo. However, inhibiting the 
actions of Elk1 and GR simultaneously did not 
have co-regulatory effects on αvβ6 expression 
over and above inhibiting either transcription 
factor singularly. It is, therefore, very likely that 
other factors that may bind the repressor region 
are involved in the basal repression of the ITGB6 
gene, some of which may have combined 
additive effects on αvβ6 repression. However, it 
is beyond the scope of this manuscript to 
investigate them all. Fundamentally, a consistent 
effect of manipulating Elk1 on ITGB6 promoter, 
gene and protein expression was observed both 
in vitro and in vivo highlighting a novel and 
important function for Elk1 in ITGB6 regulation. 
These data are the first description of aberrant 
Elk1 expression in any fibrotic condition, and 
could help explain the mechanisms driving 
enhanced αvβ6 expression in IPF. Elk1 is an X-
linked gene (ensemble.org), thus defects in a 
single allele will have greater effects in males, 
which may potentially explain the gender 
differences associated with IPF [35]. Levels of 
Elk1 protein were reduced in lung tissue 
homogenates and histological sections from PF 
patients, and furthermore, tissue ChIP analysis 
revealed that Elk1 binding to the ITGB6 
promoter was reduced in PF tissue. Expression 
of ITGB6 is restricted to epithelium, therefore 
these data suggest that a defect in total lung Elk1 
is likely to play a role in de-repression of 
epithelial v6 integrin expression observed in 
fibrotic lung tissue. While the mechanisms 
regulating decreased Elk1 expression in 
pulmonary fibrosis are unclear, Elk1 is a target 
of mir-185 (microRNA.org), which is increased 
in lung tissue from patients suffering from 
rapidly progressive IPF [36]. 
While the focus of this manuscript is on the 
effect of Elk1 on expression of epithelial 
restricted v6 integrins it is apparent that 
global loss of Elk1 expression in IPF could have 
implications on multiple pathways in many other 
cells types involved in the pathogenesis of IPF. 
Elk1 signalling has been implicated in regulating 
elastin expression in lung fibroblasts [37], 
hyaluronan expression in dermal fibroblasts 
[38], and alpha-smooth muscle actin in vascular 
smooth muscle cells [39], all of which could 
have implications for fibrogenesis. Our own in 
silico analysis has highlighted the presence of 
Elk1 binding motifs in the promoters of several 
fibrotic genes including alpha smooth muscle 
actin, the β8 integrin subunit and TGFRII 
amongst others. Loss of Elk1 may also impact 
expression of other integrins, such as the v1 
integrin, which has recently been implicated in 
fibrogenesis in multiple organs [40]. 
We propose a novel function for the 
transcription factor Elk1 in fibrosis. Following 
epithelial cell injury Elk1 serves to limit the 
repair response through repression of ITGB6 
transcription and therefore αvβ6 integrins. 
Where there is failure of repression through, in 
part, loss/interruption of Elk1 
expression/signalling, fibrogenesis may ensue 
through enhanced and sustained expression of 
ITGB6. In summary, this study describes a novel 
function for the transcription factor Elk1 in 
contributing to repression of v6 integrins in 
the pulmonary epithelium and show that reduced 
Elk1-mediated repression is important in driving 
the increased v6 integrin expression and 
collagen deposition observed in pulmonary 
fibrosis.  
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FIGURE LEGENDS 
Figure 1: The ITGB6 Gene Promoter Contains a Large Repressor Region 
A: Schematic diagram demonstrating the series of deletion mutants of the full length pGL3-ITGB6 
promoter luciferase reporter construct 
B: iHBECs were transfected with the either empty pGL3 vector, full length ITGB6 promoter reporter 
or a series of ITGB6 promoter deletion mutants. After four hours luciferase activity was measured to 
determine promoter activity. Data expressed as mean relative firefly/renilla ratio ± SEM from three 
independent experiments. * = p < 0.05 
C: In silico analysis revealed the presence of several transcription factor binding sites between -818 
and -731 from the TSS. This schematic diagram shows these transcription factor binding sites. 
Figure 2: v6 is repressed by Elk1 binding to the ITGB6 promoter at –772 and –752 
A: Basal binding of Elk1 to the repressor region of the endogenous ITGB6 promoter (-934 to -753) 
and a control region (-1604 to -1497) was assessed by ChIP in iHBECs. Binding of Elk1 above IgG 
binding levels was detected at the repressor region but not at the control region. Data are expressed as 
mean relative binding (relative to IgG) ± SEM from three independent experiments. * = p < 0.05 
B: SDM of Elk1 sites located at either -772, or -752 or both was performed. H647 cells were 
transfected with either non-mutated pGL3-ITGB6 reporter or either of the mutated constructs for 24 
hours. ChIP was performed for endogenous Elk1. Relative binding above IgG was calculated relative 
to the full length, non-mutated promoter construct. Figure shows mean relative binding ± SEM from 
three independent experiments. ** = p < 0.005 
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C: SDM of Elk1 sites located at either -772, or -752 or both was performed. iHBECs were transfected 
with these constructs and luciferase activity measured. Data expressed as mean relative firefly/renilla 
ratio ± SEM from three indepdent experiments. * = p < 0.05 
D: iHBECs were transfected with Elk1 or control siRNA and Elk1 expression measured by western 
blotting. Figure is representative of three independent experiments. The ratio of Elk1: GAPDH as 
calculated by densitometry is shown beneath the bands. 
E: iHBECs were transfected with Elk1 or control siRNA and ELK1 mRNA assessed. Data expressed 
as mean ELK1 expression ± SEM from two independent experiments. * = p < 0.05  
F: iHBECs were cotransfected with Elk1 or control siRNA with the full length ITGB6 promoter 
reporter. Data expressed as mean relative firefly/renilla ± SEM from three independent experiments. * 
= p < 0.05 
G: iHBECs were transfected with either control siRNA or Elk1 siRNA and αvβ6 expression assessed 
after two days. Grey line = negative control; black solid line = control siRNA; dotted line = Elk1 
siRNA. Histogram is representative of three independent experiments 
H: Bar chart shows amalgamated data from experiments shown in Figure 2G expressed as fold change 
MFI. * = p < 0.05 
Figure 3: Glucocorticoid Receptor, but not Progesterone Receptor, represses v6 
A: iHBECs transfected with the ITGB6 promoter reporter (black bars) or an empty vector control 
(white bars) were stimulated with 2 ng/ml TGF, 10 μM dexamethasone or TGF and 
dexamethasone together. Data expressed as mean relative firefly/ renilla ratio ± SEM from three 
independent experiments. * = p < 0.05 
B: SAECs were stimulated with dexamethasone for three days and v6 assessed. Grey line = 
negative control. Solid line = 0 μM. Dotted line = 10 M. Histogram is representative of three 
independent experiments. 
C: The data shown in Figure 3B are expressed as a bar chart. Figure shows amalgamated data from 
three independent experiments expressed as fold change MFI. ** = p < 0.01 
D: iHBECs were transfected with control or GR siRNA and GR protein expression determined by 
western blot to confirm GR knockdown. Figure is representative of three independent experiments. . 
The ratio of GR: GAPDH as calculated by densitometry is shown beneath the bands. 
E: iHBECs were transfected with control or GR siRNA and αvβ6 assessed after two days. Grey line = 
negative control; black solid line = control siRNA; black dotted line = GR siRNA. Histogram is 
representative of three independent experiments. 
F: The data shown in Figure 3E are expressed as a bar chart. Figure shows amalgamated data from 
three independent experiments expressed as fold change MFI. ** = p < 0.01 
G: iHBECs were transfected with either an ITGB6 promoter reporter (black bars) or an empty vector 
control (white bars) and stimulated with TGFng/ml, progesterone (10 μM) or TGF and 
progesterone in combination. Data are expressed as mean relative firefly/renilla ratio ± SEM from 
three independent experiments. ** = p < 0.01 
H: iHBECs were stimulated with 10μM progesterone and ITGB6 mRNA measured by QPCR over 24 
hours. Data are expressed as mean fold change relative to 0 hour ± SEM from three independent 
experiments. 
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I: SAECs were stimulated with 10 μM progesterone and v6 was assessed. Grey line = negative 
control. Solid line = 0 μM. Dotted line = 10 M progesterone. Histogram is representative of three 
independent experiments. 
Figure 4: Inhibiting the Actions of Elk1 and GR Simulataneously Does Not have an Additive 
Effect on αvβ6 Repression 
A: iHBECs were transfected with Elk1 siRNA for 24 hours then stimulated with either 0 or 10µM 
dexamethasone. αvβ6 expression was determined after two days. Figure shows amalgamated data 
from three independent experiments. Data are expressed as fold change in MFI. * = p<0.05 
B: iHBECs were left unstimulated or stimulated with 2ng/ml TGFβ, 10µM dexamethasone or both 
agonists in combination for three days. αvβ6 expression was determined by flow cytometry. Figure 
shows amalgamated data from three independent experiments. Data are expressed as fold change in 
MFI. * = p<0.05 
C: iHBECs were transfected with either control siRNA, Elk1 siRNA, GR siRNA or both siRNAs in 
combination for 24 hours. The cells were then treated with 0 or 2ng/ml TGFβ for two days. αvβ6 
expression was measured by flow cytometry. Figure shows amalgamated data from three independent 
experiments. Data are expressed as fold change in MFI. * = p<0.05, ** = p<0.01 
Figure 5: Loss of Elk1 in vivo results in an exaggerated response to bleomycin-induced lung 
fibrosis. 
A: Itgb6 mRNA levels were measured in lung homogenates by QPCR and were significantly elevated 
in bleomycin instilled Elk1
-/0
 mice (n = 5 mice), compared with bleomycin-treated Elk1
+/0
 control 
mice (n = 7 mice). * = p < 0.05 
B: Total lung collagen, assessed by hydroxyproline levels, was significantly elevated in bleomycin 
instilled Elk1
-/0
 mice (n = 5 mice) compared with Elk1
+/0
 controls (n = 7 mice). * = p < 0.05 
C: Lung collagen was stained using Masson’s trichrome. Nikon NIS Elements was utilised to image 
an entire lung lobe from an Elk
+/0
 animal to demonstrate the deposition of collagen across the lobe. 
Figure shows a representative single lung lobe from an Elk
+/0 
animal treated with bleomycin (n = 4 
mice). 
D: Lung collagen was stained using Masson’s trichrome. Nikon NIS Elements was utilised to image 
an entire lung lobe from an Elk1
-/0
 animal to demonstrate the deposition of collagen across the lobe. 
Figure shows a representative single lung lobe from an Elk1
-/0 
animal treated with bleomycin (n = 4 
mice). 
E: Histological sections of lung from Elk1
-/0 
and Elk1
+/0
 animals following a bleomycin model of lung 
fibrosis were stained with Masson’s trichrome and for αvβ6 and pSmad2 by immunohistochemistry. 
All images were acquired using Nikon NIS Elements and are representative of a minimum of 3 
(maximum of 5) animals. i) Saline treated Elk1
+/0
 animal stained with Masson’s trichrome. ii) Saline 
treated Elk1
-/0
 animal stained with Masson’s trichrome. iii) Bleomycin treated Elk1+/0 animal stained 
with Masson’s trichrome. iv) Bleomycin treated Elk1-/0 animal stained with Masson’s trichrome. v) 
Bleomycin treated Elk1
+/0
 animal immunostained for αvβ6. vi) Bleomycin treated Elk1+/0 animal 
immunostained for pSmad2. vii) Bleomycin treated Elk1
-/0
 animal immunostained for αvβ6. viii) 
Bleomycin treated Elk1
-/0
 animal immunostained for pSmad2. 
F: Histological sections of lung from Elk1
-/0 
and Elk1
+/0
 animals following a bleomycin model of lung 
fibrosis were stained immunohistochemically for pSmad2 (see Figure 5E vi and viii). pSmad2 
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positive nuclei were quantified. Data are expressed as mean brown nuclei per field of view in 
bleomycin-treated Elk1
+/0
 (n=4) and Elk1
-/0
 (n=5) animals.  
G: Animals were instilled with either bleomycin or saline and treated with either PBS or 
dexamethasone daily. Itgb6 mRNA levels were measured in lung homogenates by QPCR after 14 
days and were significantly elevated in bleomycin instilled PBS treated mice (n = 12 mice), compared 
with saline instilled PBS treated mice (n = 7 mice). * = p < 0.05 
Figure 6: Expression of Elk1 is reduced in pulmonary fibrosis 
A: Relative expression of ITGB6 mRNA in NF (n = 6 donors) and PF (n = 6 donors) human lung 
tissue was assessed by QPCR. Data are expressed as relative mRNA expression compared with NF 
samples. Line demonstrates median.  
B: Binding of Elk1 to the ITGB6 promoter in NF and PF tissue measured by ChIP. Data expressed as 
relative binding to the ITGB6 promoter compared with IgG control and the median expressed. 
Relative binding of 1 or below demonstrates no binding to the promoter above IgG. 
C: Densitometry analysis of Elk1 expression was in whole lung extracts from NF (n = 8 donors) and 
PF (n = 14 donors) donors. Data expressed as a ratio of Elk1 band intensity: GAPDH band intensity. 
** = p < 0.01 
D: Representative immunoblot showing Elk1 and GAPDH expression in NF (n = 4 donors) and PF (n 
= 5 donors) lung tissue. The ratio of Elk1: GAPDH as calculated by densitometry is shown beneath 
the bands. 
E: Immunoblot showing Elk1 and GAPDH protein expression in Elk1
+/0
 (n=2 mice) and Elk1
-/0
 (n=2 
mice) animals. The ratio of Elk1: GAPDH as calculated by densitometry is shown beneath the bands. 
F: Histological sections of lung from control (n = 4 donors) and PF (n = 4 donors) donors was 
immunostained for αvβ6 and Elk1. All images were acquired using Nikon NIS Elements and are 
representative of the donor samples used. i) Lung tissue from a control donor was stained for αvβ6. ii) 
Lung tissue from a PF donor was stained for αvβ6. iii) Lung tissue from a control donor was stained 
for Elk1. iv) Lung tissue from a PF donor was stained for Elk1. 
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